Table 2 –
Reference | No. of cases | Findings | PLND at time of aborted RC | Chemotherapy after aborted RC | Median follow-up (mo) | Survival | Comment |
---|---|---|---|---|---|---|---|
Guzzo et al [21] | 35 | Grossly enlarged LNs: 91% pT4:23% |
31 | 30 | 18.5 | 60% died from the disease 31% alive with evidence of disease persistence or re-progression. 9% alive with no evidence of disease |
Subsequent salvage RC: 23%. 43% had no evidence of disease progression at a mean time of 10 mo after salvage RC |
Yafi et al [22] | 31 | Clinical T≥2: 45% Clinical N1: 10% Pathological T4b: 55 Pathological N2–3: 45% |
20 | 23 | 10 | 2-yr OS: 41% 5-yr OS: 0% Patients who underwent RPLND trended toward improved OS (24 vs 10 mo, p = 0.09) |
35% received CHT with intention to surgical consolidation, only 9% rendered resectable |
CHT = chemotherapy; LN = lymph node; OS = overall survival; PLND = pelvic lymph node dissection; RC = radical cystectomy.